Wall Street brokerages expect Meridian Bioscience, Inc. (NASDAQ:VIVO) to post earnings of $0.10 per share for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Meridian Bioscience’s earnings. The highest EPS estimate is $0.12 and the lowest is $0.07. Meridian Bioscience reported earnings per share of $0.18 during the same quarter last year, which would indicate a negative year over year growth rate of 44.4%. The firm is scheduled to report its next earnings report before the market opens on Tuesday, July 30th.
On average, analysts expect that Meridian Bioscience will report full-year earnings of $0.56 per share for the current fiscal year, with EPS estimates ranging from $0.52 to $0.62. For the next financial year, analysts forecast that the business will report earnings of $0.54 per share, with EPS estimates ranging from $0.49 to $0.62. Zacks’ EPS calculations are an average based on a survey of analysts that cover Meridian Bioscience.
Meridian Bioscience (NASDAQ:VIVO) last posted its quarterly earnings results on Tuesday, April 30th. The company reported $0.19 EPS for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.04. The business had revenue of $50.25 million for the quarter, compared to analysts’ expectations of $50.03 million. Meridian Bioscience had a return on equity of 18.58% and a net margin of 13.29%. The business’s quarterly revenue was down 11.0% on a year-over-year basis. During the same period last year, the firm earned $0.21 earnings per share.
VIVO has been the topic of several research reports. Robert W. Baird initiated coverage on Carbon Black in a report on Wednesday, April 3rd. They issued an “outperform” rating and a $20.00 target price on the stock. BidaskClub lowered Walgreens Boots Alliance from a “sell” rating to a “strong sell” rating in a research report on Monday, June 24th. Piper Jaffray Companies lifted their price target on DexCom to $173.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 1st. Zacks Investment Research upgraded SCHNEIDER ELEC /ADR from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research report on Friday, July 5th. Finally, ValuEngine upgraded Yandex from a “hold” rating to a “buy” rating in a research report on Saturday, April 13th. Three analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $11.45.
In other Meridian Bioscience news, Director James M. Anderson bought 5,000 shares of the company’s stock in a transaction on Thursday, May 16th. The stock was acquired at an average price of $11.37 per share, for a total transaction of $56,850.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John P. Kenny bought 20,000 shares of the company’s stock in a transaction on Wednesday, May 8th. The shares were acquired at an average price of $11.49 per share, with a total value of $229,800.00. Following the transaction, the chief executive officer now directly owns 83,000 shares of the company’s stock, valued at $953,670. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 32,000 shares of company stock valued at $366,170. 2.00% of the stock is currently owned by company insiders.
Several large investors have recently made changes to their positions in the business. Thrivent Financial for Lutherans boosted its position in shares of Meridian Bioscience by 2.2% during the fourth quarter. Thrivent Financial for Lutherans now owns 30,198 shares of the company’s stock valued at $524,000 after buying an additional 664 shares during the period. LPL Financial LLC boosted its position in shares of Meridian Bioscience by 4.4% during the fourth quarter. LPL Financial LLC now owns 22,259 shares of the company’s stock valued at $386,000 after buying an additional 934 shares during the period. Comerica Bank boosted its position in shares of Meridian Bioscience by 2.3% during the first quarter. Comerica Bank now owns 42,420 shares of the company’s stock valued at $562,000 after buying an additional 937 shares during the period. Meeder Asset Management Inc. boosted its position in shares of Meridian Bioscience by 196.7% during the first quarter. Meeder Asset Management Inc. now owns 1,552 shares of the company’s stock valued at $27,000 after buying an additional 1,029 shares during the period. Finally, Texas Permanent School Fund boosted its position in shares of Meridian Bioscience by 4.0% during the fourth quarter. Texas Permanent School Fund now owns 27,748 shares of the company’s stock valued at $482,000 after buying an additional 1,073 shares during the period. Institutional investors and hedge funds own 90.35% of the company’s stock.
NASDAQ:VIVO traded up $0.08 on Friday, reaching $11.47. 202,004 shares of the company’s stock traded hands, compared to its average volume of 333,790. The company has a debt-to-equity ratio of 0.23, a quick ratio of 4.31 and a current ratio of 6.01. The stock’s 50-day moving average is $11.53. The stock has a market capitalization of $487.35 million, a price-to-earnings ratio of 15.50 and a beta of 0.33. Meridian Bioscience has a 12 month low of $10.77 and a 12 month high of $19.84.
About Meridian Bioscience
Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.
Further Reading: 52-Week High/Low Prices For Stock Selection
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.